Today and tomorrow the FH Foundation will be representing the familial hypercholesterolemia (FH) community at the U.S. Food & Drug Administration (FDA) Endocrinologic & Metabolic Drugs Advisory Committee (EMDAC) Meeting in Washington, D.C.  

As a patient-centered research advocacy organization, the need for more safe and effective treatments of FH has always been a top priority for the FH Foundation.  This historic meeting focuses on a new class of LDL-lowering therapies, PCSK9 inhibitors.  These therapies may represent a major step forward in reducing the high risk of heart disease for those living with FH. 

For more information on the meeting and agenda CLICK HERE

Stay tuned by following us on Twitter: 

https://twitter.com/TheFHFoundation